March 16th 2012
Recognition of breast cancer subtypes and research into their underlying biologies is driving the development of new therapies.
Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer
Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.
March 15th 2012
Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting
Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.
The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.
Pictures from the Annual Miami Breast Cancer Conference, at the Fontainebleau Miami Beach hotel, in Florida.
March 14th 2012
Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.
The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.
March 12th 2012
As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.
March 18th 2011
In this podcast, Maisam Fazel, FRCS, MS, MB BChir, discusses his research into a checklist for breast cancer surgeons.
March 16th 2011
Dr. Daniel Osman, director of the Miami Breast Cancer Conference, on Designing the Program for the MBCC
March 14th 2011
Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training
As the number of breast cancer survivors grows, so does the emphasis on establishing individualized survivorship plans
Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response
With thousands of clinical trials in play, many oncology specialists are reluctant to embrace findings from newly-released studies
Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy
Personalized treatment in oncology is a popular concept these days, but the goal remains elusive
March 11th 2011
It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ